Literature DB >> 625068

Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo.

O Alabaster, M Cassidy.   

Abstract

Maytansine is a new drug undergoing clinical investigation. It has functional similarities to vincristine. Maytansine and vincristine were given to CDF1 mice with P388 leukemic ascites, and the cytokinetic response of the tumor cells was analyzed with a flow microfluorometer; mithramycin was used as the DNA fluorochrome. The results indicated a similar series of cytokinetic effects after administration of both drugs, though these effects were greater and more persistent after maytansine was given. Although both drugs produced some degree of multinucleation and endoreduplication, vincristine produced a discrete population of cells with a DNA content (fluorescence) equivalent to octoploidy (8C). Microscopy of the sorted 8C cells at 24 hours indicated 54% multinucleation and 33% mitotic figures. Most cells remained blocked in the G1-phase for at least 96 hours after administration of both drugs, which indicated that rapid DNA content distributions can be used to determine not only the effects of drugs on cell cycle distribution but also the duration of drug action.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 625068     DOI: 10.1093/jnci/60.3.649

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.

Authors:  A T McGown; D G Poppitt; R Swindell; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Studies on the so-called "synchronization therapy" of tumors with vincristine.

Authors:  B Schultze; W Jellinghaus; U Basler; J Dettmer; W Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  Treatment of artificially-induced pulmonary metastases with fractionated doses of vincristine and/or radiation therapy.

Authors:  D J Grdina; R A White
Journal:  Clin Exp Metastasis       Date:  1983 Jan-Mar       Impact factor: 5.150

4.  Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Authors:  Mark Barok; Minna Tanner; Katri Köninki; Jorma Isola
Journal:  Breast Cancer Res       Date:  2011-04-21       Impact factor: 6.466

5.  Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.

Authors:  M Sehested; P B Jensen; T Skovsgaard; N Bindslev; E J Demant; E Friche; L Vindeløv
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

6.  Cytotoxic effects of vincristine on tumour subpopulations separated from pulmonary nodules.

Authors:  D J Grdina; R A White; J J Stragand
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

7.  Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy.

Authors:  Mike-Andrew Westhoff; Marie Schuler-Ortoli; Daniela Zerrinius; Amina Hadzalic; Andrea Schuster; Hannah Strobel; Angelika Scheuerle; Tiana Wong; Christian Rainer Wirtz; Klaus-Michael Debatin; Aurelia Peraud
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.